After rancorous 2011, BIO expects some congressional rematches in 2012
This article was originally published in Scrip
While 2011 could easily be remembered in Washington as a year when political brinksmanship among Democrats and Republicans led to not much getting done by Congress, one piece of legislation important to the biopharmaceutical industry, and to US innovation in general, managed to rise out of the shadow of the abyss and be enacted – the America Invents Act.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.